natgillin/translations-raw huggingface dataset:
► If you have only one sore injection site (lesion) and the tissue damage (necrosis) is not too extensive you may continue using Betaferon.
Če vam poči koža zaradi otekanja ali iztekanja tekočine z mesta injiciranja: ► prenehajte z injiciranjem zdravila Betaferon in se posvetujte z zdravnikom, ► če je poškodovano le eno mesto injiciranja (lezija) in poškodbe tkiva (nekroza) niso obsežne, lahko nadaljujete z uporabo zdravila Betaferon, ► če imate več poškodovanih mest injiciranja (multiple lezije), morate prenehati uporabljati zdravilo Betaferon, dokler se koža ne zaceli.
If this is severe a doctor may have to remove foreign matter and dead tissue (debridement) and, less often, skin grafting is required and healing may take up to 6 months.
bo morda moral zdravnik odstraniti tujke in mrtvo tkivo (debri).
sinusitis, cough increased, shortness of breath (dyspnoea) - diarrhoea, constipation, nausea, vomiting, abdominal pain - rises in the blood levels of liver enzymes (will show up in blood tests) - skin disorder, rash - muscle stiffness (hypertonia), painful muscles (myalgia), muscular weakness (myasthenia),
- driska, zaprtje, občutek siljenja na bruhanje, bruhanje, bolečine v trebuhu - povečane vrednosti jetrnih encimov v krvi (pokažejo krvne preiskave)
− 3-month pack with 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali - 3-mesečno pakiranje s 3 x 15 posameznimi pakiranji; vsako posamezno pakiranje vsebuje 1 vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
− 1 pre-filled syringe of solvent for Betaferon (sodium chloride solution 5.4 mg/ml (0.54% w/v)),
(raztopina natrijevega klorida 5,4 mg/ml (0,54 % m/v)).
Use green triple pack No. 3 for treatment days 13, 15 and 17 Use blue triple pack No. 4 for treatment days 19, 21 and 23
Uporabite modro tridelno pakiranje 4 za 19., 21. in 23. dan zdravljenja.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF MULTI-MONTH PACK (INCLUDING BLUE BOX)
ŠKATLA Z VEČMESEČNIMI PAKIRANJI (S PODATKI ZA 'BLUE BOX')
Anaphylactic reactions
- resne alergijske (anafilaktične) reakcije
Asthenia *
Bolezni sečil
Contents of the pack and other information
Vsebina pakiranja in dodatne informacije Kaj vsebuje zdravilo Betaferon
Then draw up solution as far as the 1.0 ml mark on the syringe: 1.0 ml for the injections at day 19, 21 and 23 of therapy.
1,0 ml za injiciranje na 19., 21. in 23. dan zdravljenja
Metabolism and nutrition disorders
Motnje reprodukcije in dojk menoragija
See section 2.
II, v drugem delu tega navodila).
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 250 mcg (8 m IU) per ml after reconstitution
250 mikrogramov (8,0 milijonov i.e.)/ml po rekonstituciji
See ‘Warnings and precautions' in section 2 for more information and what to do, if you experience an injection site reaction.
Če opazite reakcije na mestu injiciranja, glejte poglavje 2, Opozorila in previdnostni ukrepi.
Aspartate aminotransferase increased (SGOT > 5 times baseline) × Λ * °
(SGOT > 5-kratna izhodiščna vrednost) ×
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON OF MULTIPACK (INCLUDING BLUE BOX)
ŠKATLA Z VEČ PAKIRANJI (S PODATKI ZA 'BLUE BOX')
− Titration pack for dose titration with 4 differently coloured and numbered triple packs: - yellow, with number “1”(treatment days 1, 3 and 5; 0.25-ml syringe marking), - red, with number “2” (treatment days 7, 9 and 11; 0.5-ml syringe marking), - green, with number “3” (treatment days 13, 15 and 17; 0.75-ml syringe marking), - blue, with number “4” (treatment days 19, 21 and 23; 0.25, 0.5, 0.75 and 1-ml syringe marking)
− modro, označeno s številko »4« (za 19., 21. in 23. dan zdravljenja; oznake 0,25, 0,5, 0,75
Driving and using machines
POSTOPEK IN POT UPORABE ZDRAVILA
− Pack with 14 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
vialo s praškom, 1 napolnjeno injekcijsko brizgo z vehiklom, 1 adapter za vialo z iglo, 2 alkoholni blazinici ali
Posology
PREDEL
6.1 List of excipients:
FARMACEVTSKI PODATKI 6.1 Seznam pomožnih snovi
STATEMENT OF ACTIVE SUBSTANCE(S) 1 ml contains 250 microgram (8.0 million IU) interferon beta-1b when reconstituted.
1 ml vsebuje 250 mikrogramov (8,0 milijonov i.e.) interferona beta-1b po rekonstituciji.
Betaferon is indicated for the treatment of
4.1 Terapevtske indikacije Zdravilo Betaferon je indicirano za zdravljenje
METHOD AND ROUTE OF ADMINISTRATION For subcutaneous injection after reconstitution with 1.2 ml of solvent.
Po rekonstituciji z 1,2 ml vehikla zdravilo injicirajte subkutano.
1.2 ml sodium chloride solution 5.4 mg/ml
Vehikel za rekonstitucijo Betaferona 1,2 ml raztopine natrijevega klorida 5,4 mg/ml
Sterile white to off-white powder.
prašek in vehikel za raztopino za injiciranje sterilen bel do umazano bel prašek
B) Getting ready to inject
B) Priprava na injiciranje
• 3 pre-filled syringes with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml
1 napolnjena injekcijska brizga z 1,2 ml vehikla: raztopina natrijevega klorida 5,4 mg/ml
If there is no response to treatment after two to three days, doctors should re-evaluate the patient and consider alternative treatments.
Če po dveh ali treh dneh ni odziva na zdravljenje, mora zdravnik ponovno pregledati bolnika in po presoji uvesti alternativno zdravljenje.
The European Commission granted a marketing authorisation valid throughout the European Union for Altargo to Glaxo Group Ltd on 24 May 2007.
Evropska komisija je dovoljenje za promet z zdravilom Altargo, veljavno po vsej Evropski uniji, odobrila družbi Glaxo Group Ltd dne 24. maja 2007.
In all five studies, the main measure of effectiveness was the proportion of patients whose infections had cleared up after the end of treatment.
Glavno merilo učinkovitosti v vseh petih študijah je bil delež bolnikov, pri katerih so okužbe po zaključku zdravljenja izginile.
It is used for short-term treatment of superficial skin infections.
Uporablja se za kratkotrajno zdravljenje povrhnjih okužb kože.
The effects of Altargo were first tested in experimental models before being studied in humans.
Učinki zdravila Altargo so bili najprej preizkušeni na poskusnih modelih, nato pa so jih raziskali pri ljudeh.
The Committee for Medicinal Products for Human Use (CHMP) decided that Altargo's benefits are greater than its risks for the short term treatment of the following superficial skin infections:
Odbor za zdravila za uporabo v humani medicini (CHMP) je odločil, da so koristi zdravila Altargo večje od z njim povezanih tveganj pri kratkotrajnem zdravljenju naslednjih povrhnjih okužb kože:
Altargo should only be used on the skin.
Zdravilo Altargo se uporablja samo na koži.
It is derived from a compound produced by certain types of fungus.
Je derivat spojine, ki jo proizvajajo določene vrste gliv.
Altargo can be used in patients from the age of nine months, but in patients under 18 years of age, the area to be treated should not be more than 2% of the body's surface.
Zdravilo Altargo se lahko uporablja pri bolnikih, starejših od devetih mesecev, vendar pa pri bolnikih, mlajših od 18 let, prizadeto območje ne sme presegati 2 % telesne površine.
• infected small lacerations, abrasions or sutured wounds.
• okužene manjše raztrganine, odrgnine ali zašite rane.
Altargo has been studied in five main studies involving over 3,000 patients aged from 9 months upwards.
Zdravilo Altargo so preučevali v petih glavnih študijah, ki so zajele več kot 3.000 bolnikov, starih od 9 mesecev dalje.
It works by blocking the bacteria's ribosomes (the parts of the cells where proteins are produced), inhibiting the growth of the bacteria.
Deluje tako, da zavira ribosome bakterij (dele celice, na katerih poteka sinteza proteinov) in tako preprečuje rast bakterij.
What is the risk associated with Altargo?
Kakšna tveganja so povezana z zdravilom Altargo?
The data presented were insufficient to support the use of Altargo in the treatment of infected
Predloženi podatki niso bili zadostni za utemeljitev uporabe zdravila Altargo pri zdravljenju
However, these two studies found that Altargo was not sufficiently effective in the treatment of abscesses (cavities containing pus) or of infections known or likely to be caused by MRSA.
Vendar pa se je v teh dveh študijah izkazalo, da zdravilo Altargo ni bilo dovolj učinkovito pri zdravljenju abscesov (ognojkov) ter okužb, za katere je znano ali verjetno, da so jih povzročili sevi MRSA.
Altargo is an antibiotic medicine.
Zdravilo Altargo je antibiotik.
What benefit has Altargo shown during the studies?
Kakšne koristi je zdravilo Altargo izkazalo med raziskavami?
It can be used to treat impetigo (a skin infection causing crusting scabs), and small infected lacerations (cuts), abrasions (grazes) and wounds that have been sutured (stitched).
Lahko se uporablja za zdravljenje impetiga (okužbe kože, ki povzroča skorjaste kraste) ter okuženih manjših raztrganin (vreznin), odrgnin in zašitih ran.
Two studies were carried out in patients with impetigo.
Dve študiji sta bili izvedeni pri bolnikih z impetigom.
It is applied onto the affected area as a thin layer twice a day for five days.
Na prizadeti predel kože se nanese tanko plast zdravila dvakrat na dan, pri čemer celotno zdravljenje traja pet dni.
However, it may be used to treat infections caused by other types of Staphylococcus aureus.
Lahko pa se uporablja za zdravljenje okužb, ki jih povzročajo drugi sevi Staphylococcus aureus.
The Committee recommended that Altargo be given marketing authorisation.
Odbor je priporočil, da se za zdravilo Altargo odobri dovoljenje za promet z zdravilom.
For the treatment of infected skin wounds, Altargo and cefalexin had similar response rates: when the results of both skin wound studies were taken together, around 90% of both groups of patients responded to treatment.
Pri zdravljenju okuženih kožnih ran sta bili stopnji odziva na zdravilo Altargo in cefaleksin podobni: ocena kombiniranih rezultatov obeh študij kožnih ran je pokazala, da se je na zdravljenje odzvalo približno 90 % bolnikov iz obeh skupin.
Prescribers should consider official guidance on the
Zdravniki, ki predpisujejo zdravilo, morajo upoštevati uradne smernice o uporabi
Altargo should not be used to treat infections known or thought likely to be due to methicillin-resistant Staphylococcus aureus (MRSA), as it may not work against this type of infection.
Zdravila Altargo se ne sme uporabljati za zdravljenje okužb, za katere je bilo ugotovljeno ali pri katerih obstaja sum, da so jih povzročili sevi Staphylococcus aureus (MRSA), odporni na meticilin, ker mazilo morda ne bo učinkovito proti tej vrsti okužbe.
The full list of bacteria against which Altargo is active can be found in the Summary of Product
Celoten seznam bakterij, proti katerim je zdravilo Altargo učinkovito, najdete v Povzetku glavnih značilnosti zdravila.
The most common side effect with Altargo (seen in between 1 and 10 patients in 100) is irritation at the site of application.
Najpogostejši neželeni učinek zdravila Altargo (opažen pri 1 do 10 bolnikih izmed 100) je draženje na mestu nanosa.
How has Altargo been studied?
Kako je bilo zdravilo Altargo raziskano?
Altargo was at least as effective as fusidic acid, with 314 (99.1%) of 317 and 141 (94.0%) of 150 patients, respectively, responding to treatment.
Zdravilo Altargo je bilo vsaj tako učinkovito kot fusidinska kislina, saj se je na zdravljenje odzvalo 314 (99,1 %) od 317 bolnikov, pri fusidinski kislini pa 141 (94,0 %) od 150 bolnikov.
EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) ALTARGO EPAR summary for the public
EVROPSKO JAVNO POROČILO O OCENI ZDRAVILA (EPAR) ALTARGO
In patients with impetigo, Altargo was more effective than placebo, with 119 (85.6%) of the 139 patients using Altargo and 37 (52.1%) of the 71 using placebo responding to treatment.
Pri bolnikih z impetigom je bilo zdravilo Altargo učinkovitejše od placeba, saj se je na zdravljenje odzvalo 119 (85,6 %) od 139 bolnikov, ki so jemali zdravilo Altargo, in 37 (52,1 %) od 71 bolnikov, ki so jemali placebo.
Altargo should not be used in people who may be hypersensitive (allergic) to retapamulin or any of the
Zdravila Altargo ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) retapamulin ali katerokoli drugo sestavino zdravila.
The active substance in Altargo, retapamulin, is an antibiotic belonging to the ‘pleuromutilin' class.
Zdravilna učinkovina zdravila Altargo, retapamulin, je antibiotik iz skupine „pleuromutilinov“.
compared the effects of five days' treatment with Altargo to those of cefalexin (an oral antibiotic medicine): two studies were carried out in a total of 1,918 patients with infected skin wounds, and the final study was carried out in 545 patients with infected dermatitis (skin inflammation).
V ostalih treh študijah so učinke petdnevnega zdravljenja z zdravilom Altargo primerjali z učinki cefaleksina (peroralnega antibiotika): dve študiji sta bili izvedeni s skupno 1.918 bolniki z okuženimi kožnimi ranami, končna študija pa je bila izvedena s 545 bolniki z infekcijskim dermatitisom (kožnim vnetjem).
Altargo is an ointment that contains the active substance retapamulin.
Zdravilo Altargo je mazilo, ki vsebuje zdravilno učinkovino retapamulin.
The first compared the effects of five days' treatment with Altargo to those of placebo (a dummy treatment) in 213 patients, and the second compared Altargo to fusidic acid (another antibiotic ointment) in 519 patients.
zdravljenja z zdravilom Altargo primerjali z učinki placeba (zdravila brez zdravilne učinkovine) pri 213 bolnikih, v drugi pa so učinke zdravila Altargo primerjali z učinki fusidinske kisline (drugega antibiotičnega mazila) pri 519 bolnikih.
The full EPAR for Altargo can be found here.
Celotno Evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Altargo je na voljo tukaj.
The other three studies
V prvi so učinke petdnevnega
The treated area can be covered with a sterile bandage or gauze dressing.
Po nanosu mazila lahko prizadeti predel obvežete s sterilno obvezo ali prekrijete s sterilno gazo.
For the full list of all side effects reported with Altargo, see the Package
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila
(Invented) name
(Izmišljen o) ime
This summary was last updated in 06.2013.
Povzetek je bil nazadnje posodobljen dne 06.2013.
These reactions are usually mild to moderate and temporary.
Ti odzivi so ponavadi blagi do zmerni in začasni.
The tablets are given every other day, with or without food.
Tablete se dajejo vsak drugi dan, s hrano ali brez nje.
It is available as tablets: 10 mg (blue), 15 mg (orange) and 50 mg (red).
Na voljo je v obliki tablet: 10 mg (modre barve), 15 mg (oranžne barve) in 50 mg (rdeče barve).
The duration of treatment depends on the dog's response to treatment.
Trajanje zdravljenja je odvisno od odziva psa na zdravljenje.
The European Commission granted a marketing authorisation valid throughout the European Union, for Palladia on 23.09.2009.
Evropska komisija je dovoljenje za promet z zdravilom Palladia, veljavno po vsej Evropski uniji, odobrila dne 23.09.2009.
The usual dose is 3.25 mg per kilogram bodyweight, and the number of tablets to use is carefully calculated for each dog.
Običajni odmerek je 3,25 mg na kilogram telesne mase, število uporabljenih tablet pa je treba za vsakega psa pazljivo izračunati.
Other information about Palladia:
Druge informacije o zdravilu Palladia:
The main study was carried out in two phases in 151 dogs with mast cell tumours.
Glavna študija je bila izvedena v dveh fazah pri 151 psih s tumorji mastocitov.
The tablets must be given whole and should not be divided, broken or ground up.
Tablete se morajo dajati cele, ne smejo se razdeliti, prelomiti ali zdrobiti.
Treatment started with the recommended dose, but this dose was later reduced or treatment interrupted for a few days in some dogs.
Zdravljenje se je začelo s priporočenim odmerkom, vendar se je ta odmerek kasneje zmanjšal ali pa je bilo zdravljenje pri nekaterih psih za nekaj dni prekinjeno.
Dogs should be regularly monitored for side effects by the veterinarian (at the beginning of treatment, this should be at least once per week).
Neželene učinke pri psih naj redno spremlja veterinar (na začetku zdravljenja najmanj enkrat tedensko).
If broken tablets, or the vomit, urine or faeces of a treated dog comes into contact with the skin or eyes, rinse immediately with plenty of water.
Če prelomljene tablete, izbljuvki, seč ali blato zdravljenega psa pridejo v stik s kožo ali očmi, jih takoj izperite z veliko vode.
After six weeks (second phase), the study continued with all the remaining dogs receiving Palladia for an average of another four and a half months.
Po šestih tednih (druga faza) se je študija nadaljevala z vsemi preostalimi psi, ki so prejemali zdravilo Palladia povprečno naslednje štiri mesece in pol.
In case of side effects, the veterinarian might decide to lower the dose of Palladia or to stop treatment, either temporarily or permanently.
Ob neželenih učinkih se lahko veterinar odloči zmanjšati odmerek zdravila Palladia ali zdravljenje prekiniti, bodisi začasno ali stalno.
A number of studies with Palladia were carried out either in laboratory dogs or in animal patients in veterinary practices or hospitals.
Številne študije so bile izvedene bodisi z laboratorijskimi psi ali z bolnimi živalmi v veterinarskih ambulantah ali bolnišnicah.
The main measures of effectiveness were the ‘objective response' (an evaluation by the veterinarian of the way the tumour changed during treatment) and the time taken until the tumour started to get worse.
Glavno merilo učinkovitosti je bil „objektivni odziv“ (veterinarska presoja spremembe tumorja med zdravljenjem) in čas, ki je bil potreben za začetek napredovanja tumorja.
These enzymes can be found in mastcell tumours, where they are involved in the growth and spread of cancer cells, and the growth of blood vessels.
Ti encimi se nahajajo v mastocitnih tumorjih, kjer sodelujejo pri rasti in širjenju rakavih celic in rasti krvnih žil.
If the disease was getting worse, treatment with Palladia was stopped and the dog was taken out of the study.
Če se je bolezen poslabšala, so zdravljenje z zdravilom Palladia prekinili in psa izključili iz študije.
What benefit has Palladia shown during the studies?
Kakšne koristi je zdravilo Palladia izkazalo med študijami?
The most common side effects with Palladia are diarrhoea and vomiting, loss of appetite, lethargy (lack of energy), neutropenia (low white blood cell counts), difficulty moving (lameness) and weight loss.
Najpogostejši neželeni učinki zdravila Palladia so driska in bruhanje, izguba teka, letargija (pomanjkanje energije), nevtropenija (majhno število belih krvnih celic), težave s premikanjem (ohromelost) in izguba telesne mase.
By blocking these enzymes, Palladia can help to control abnormal cell growth and prevent further development of this type of tumour.
Zdravilo Palladia lahko z zaviranjem teh encimov pomaga nadzirati neobičajno rast celic in preprečuje nadaljnji razvoj te vrste tumorja.
It is used for tumours that are severe in character (grade 2 or 3), have come back, and cannot be removed with surgery.
Uporablja se pri tumorjih v resni obliki (stopnje II ali III), ki so se ponovili in jih ni mogoče kirurško odstraniti.
It should not be used in dogs that may be hypersensitive (allergic) to toceranib or any of the other ingredients.
Ne sme se uporabljati pri psih, ki so preobčutljivi za (alergične na) toceranib ali katero koli drugo sestavino zdravila.
Palladia must not be used in dogs less than two years of age or weighting less than 3 kg, in bitches that are pregnant or lactating, or in dogs intended for breeding.
Zdravilo Palladia se ne sme uporabljati pri psih, mlajših od dveh let, ki tehtajo manj kot tri kg, psicah, ki so breje ali dojijo, ali psih, ki so namenjeni za razplod.
It must not be used in dogs with bleeding in the stomach or gut.
Ne sme se uporabljati pri psih s krvavitvami v želodcu ali črevesju.
For a full list of all side effects or precautions, see the Package Leaflet.
Za celoten seznam vseh neželenih učinkov in previdnostnih ukrepov glejte navodilo za uporabo.
What is the risk associated with Palladia?
Kakšna tveganja so povezana z zdravilom Palladia?
Palladia is used to treat dogs with mast-cell tumours (a type of skin cancer).
Zdravilo Palladia se uporablja za zdravljenje psov s tumorji mastocitov (vrsto kožnega raka).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Palladia exceed the risks for the treatment of non-resectable Patnaik grade II (intermediate grade) or III (high grade), recurrent, cutaneous mast cell tumours in dogs and recommended that Palladia be given a marketing authorisation.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je sklenil, da so koristi zdravila Palladia pri zdravljenju kirurško neodstranljivih mastocitnih tumorjev stopnje II (srednje stopnje) ali III (visoke stopnje), ponovljivih podkožnih mastocitnih tumorjev pri psih večje od z njim povezanih tveganj ter priporočil, da se za zdravilo Palladia odobri dovoljenje za promet.
In a first phase (up to six weeks), Palladia was compared with placebo (a dummy treatment).
V prvi fazi (do šestih tednov) so zdravilo Palladia primerjali s placebom (zdravilom brez zdravilne učinkovine).
For Palladia-treated dogs, it also took longer for the tumour to get worse (nine to ten weeks on average) than in those receiving placebo (three weeks on average).
Prav tako je pri psih, zdravljenih z zdravilom Palladia, trajalo dlje, preden je tumor napredoval (povprečno devet do deset tednov), kot pri tistih, ki so prejemali placebo (v povprečju tri mesece).
If Palladia is taken accidentally, seek medical advice immediately and show the Package Leaflet or the label to the doctor.
Če ste zdravilo Palladia nenamerno zaužili, nemudoma poiščite zdravniško pomoč in zdravniku pokažite navodilo za uporabo ali ovojnino.
The benefit-risk balance may be found in module 6 of this EPAR.
Za razmerje med koristmi in tveganji glejte modul 6 tega evropskega javnega poročila o oceni zdravila (EPAR).
Why has Palladia been approved?
Zakaj je bilo zdravilo Palladia odobreno?
Palladia contains toceranib, which belongs to a class of medicines with anticancer activity.
Zdravilo Palladia vsebuje toceranib, ki spada v razred zdravil s protirakavim delovanjem.
The active substance in Palladia, toceranib, is a receptor tyrosine kinase inhibitor.
Zdravilna učinkovina v zdravilu Palladia, toceranib, je zaviralec receptorjev tirozin kinaze.
Dogs treated with Palladia had greater objective response rates (37%) than dogs treated with placebo (8%) after six weeks of treatment.
Po šestih tednih so bile pri psih, zdravljenih z zdravilom Palladia, objektivne stopnje odziva višje (37 %) kot pri psih, ki so bili zdravljeni s placebom (8 %).
Children should not have close contact with the medicine, or with the faeces or vomit of treated dogs.
Otroci ne smejo priti v stik z zdravilom, blatom ali izbljuvki zdravljenih psov.
A complete response (disappearance of the tumour) was seen in around 8% and a partial response (shrinkage of the tumour) was seen in around 29% of the dogs treated with Palladia.
Pri približno 8 % psov, zdravljenih z zdravilom Palladia, je bil odziv popoln (izginotje tumorja), približno 29 % psov pa se je na zdravljenje delno odzvalo (skrčenje tumorja).
What is Palladia used for?
Za kaj se zdravilo Palladia uporablja?
How has Palladia been studied?
Kako je bilo zdravilo Palladia raziskano?
How does Palladia work?
Kako zdravilo Palladia deluje?
What is Palladia?
Kaj je zdravilo Palladia?
Date of first authorisation: 17 July 2015
Datum prve odobritve: 17. julij 2015
- Your doctor will decide how many treatments you need.
- Zdravnik bo določil, koliko zdravljenj potrebujete.
30 minutes.
30 minut.
Otherwise treatment should be discontinued.
V nasprotnem primeru je treba zdravljenje ukiniti.
*p-Value is nominal.
*vrednost p je nominalna.
Currently available data are described in sections 4.8, 5.1 and 5.2.
Podatki, ki so trenutno na voljo, so opisani v poglavjih 4.8, 5.1 in 5.2.